Cholinergic agonists may produce preservation of myocardial ischaemia/reperfusion injury.
The best treatment for myocardial infarction is to restore blood flow in the ischaemic region, though it will bring new myocardial damage known as myocardial ischaemia/reperfusion (I/R) injury. Both the ischaemia preconditioning and the ischaemia postcondioning have been shown to reduce the myocardial I/R injury, but their deficits restrict wide clinical availability. It has been demonstrated that inflammation plays a critical role in the I/R injury process. Also plasma levels of cytokines and inflammation response can be regulated by specifically augmenting cholinergic signaling via the efferent vagus nerve and alpha7 subunit-containing nicotinic acetylcholine receptor (alpha7nAChR). Because cholinergic modalities, acting through vagus nerve- and/or alpha7nAChR-mediated mechanism, have been confirmed to suppress excessive inflammation during the I/R injury in kidney, liver, lung and intestine, therefore, we hypothesize that cholinergic agonists may also provide a protection for the myocardial I/R injury.
Xiong
J
J
Department of Anaesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100144, China.
Xue
F S
FS
Xu
Y C
YC
Yang
Q Y
QY
Liao
X
X
Wang
W L
WL
D000818:Animals; D018679:Cholinergic Agonists / Q000008:administration & dosage*; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D008955:Models, Cardiovascular; D018448:Models, Immunological; D009206:Myocardium / Q000276:immunology*; D011950:Receptors, Cholinergic / Q000276:immunology*; D015427:Reperfusion Injury / Q000276:immunology* / Q000517:prevention & control*
D018679:Cholinergic Agonists; D016207:Cytokines; D011950:Receptors, Cholinergic